Non-Hodgkin lymphomas in the Czech Republic

Czech version

Authors: M. Trněný
Authors‘ workplace: I. interní klinika, Všeobecná fakultní nemocnice a LF UK v Praze
Published in: Transfuze Hematol. dnes,25, 2019, No. 1, p. 81-86.
Category: Review/Educational Papers

V článku je podán přehled vývoje v oblasti non-Hodgkinových lymfomů (NHL) v České republice (ČR) v uplynulých 30 letech. Incidence lymfomů má stoupající tendenci a dosahuje nyní 14,4 nových případů na 100.000 obyvatel. Mortalita začala od roku 2001 klesat a v současné době je 5,4 na 100.000 obyvatel. Za posledních 15 let došlo zavedením imunochemoterapie ke snížení rizika úmrtí zhruba o 40 % u B NHL. Mezi důvody jsou zlepšená diagnostika, zavedení cílené imunoterapie, resp. imunochemoterapie, transplantační léčba, zlepšující se organizace péče, národní i mezinárodní spolupráce reprezentovaná Kooperativní lymfomovou skupinou. Základním nedostatkem je stále podfinancování této péče.

Overview

This article presents a review of the developments in the diagnosis and treatment of non-Hodgkin lymphomas (NHL) in the Czech Republic over the past 30 years. The incidence of lymphomas is on the increase and currently corresponds to 14.4 new cases per 100 000 inhabitants. Mortality has been on the decrease since 2001 and is currently 5.4 per 100 000 inhabitants. The past 15 years have seen the introduction of immunochemotherapy and the subsequent decrease of risk of mortality by 40% in B-NHL. The reasons for this include improved diagnostics; the introduction of targeted immune therapy or immunochemotherapy; transplantation; improving organisation of care as well as national and international collaboration represented by the Czech Cooperative Lymphoma Group. However, the basic drawback remains insufficient funding.

Keywords:

Czech Republic – non-Hodgkin lymphoma

Sources

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.

2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC 2008.

3. Swerdlow AJ, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th Edition. Lyon, IARC 2017.

4. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457–2466.

5. McLaughlin P, Grillo L, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four- dose treatment program. J Clin Oncol 1998;16:2825–2833.

6. Coiffier B, Lepage E, Herbrecht R, et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial. Blood 2000;96(Suppl 1):950.

7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.

8. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17(4):1244.

9. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee ofinternational harmonization project inlymphoma. J Clin Oncol 2007;25(5):571–578.

10. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.

11. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–3067.

12. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.

13. UZIS: Novotvary 2016 v ČR. Dostupné na: https://www.uzis.cz/katalog/zdravotnicka-statistika/novotvary.

14. Dušek L, Krejčí D, Mužík J, Jarkovský J, Pavlík T, Brabec P. Hematologické malignity v české populaci: aktuální epidemiologické trendy, predikce vývoje a jejich dopad do úhrad zdravotní péče. Transfuze Hematol dnes 2018;24(Supl 2a):5–8.

15. Trneny M, Campr V, Janikova A, et al. The improving outcome of non-Hodgkin lymphoma (NHL) within 15 years period – real world data of national-wide lymphoma project. Haematologica 2016;101:479–480.

16. Konirova E, Vitek A, Krejci M, et al. Vývoj transplantací pro lymfomy v České republice. Transfuze Hematol dnes 2018;24(Supl 2b):30.

17. Younes A, Ansell S, Fowler N, et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol 2017;14:335–346.

18. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380:45–56.

19. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531–2544.

20. Belada D, Trněný M, et al. Kooperativní lymfomové skupiny. Diagnostické a léčebné postupy u nemocných s maligními lymfomy X. vydání, dostupné na: https://www.lymphoma.cz/assets/pdf/KLS_guidelines_10_2018.pdf.

21. Janikova A, Bortlicek Z, Campr V, et al. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. Ann Hematol 2018;97:669–678.

22. Belada D, Prochazka V, Janikova A, et al. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. Leuk Res 2018;73:29–38.

23. Obr A, Prochazka V, Papajik T, et al. Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech Lymphoma Study Group registry. Leuk Lymphoma 2018; publikováno elektronicky 6. září 2018. DOI: 10.1080/10428194.2018.1508672.

24. Klener PJ, Salek D, Pytlik R, et al. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol; publikováno elektronicky 13. prosince 2018. DOI: 10.1002/ajh.25362.

25. Klener P, Fronkova E, Belada D, et al. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol Oncol 2018;36:110–115.

26. Klener P, Fronkova E, Kalinova M, et al. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematol Oncol 2018;36(1):110–115.

27. Musilova K, Devan J, Cerna K, et al. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood 2018;132:2389–2400.

28. Obr A, Prochazka V, Jirkuvova A, et al. TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2018;18:762–768.

29. Klener PJ, Trneny M, Andera L, et al. Co-targeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed refractory mantle cell lymphoma with complex karyotype changes. Blood 2018;132:42.

30. Etrych T, Daumova L, Pokorna E, et al. Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging. J Control Release 2018;289:44–55.